Nusayba A. Bagegni, MD

Nusayba A. Bagegni, MD

Associate Professor

Address:
Division of Oncology
Mail Stop 8056-0029-11
Washington University
660 South Euclid Avenue
St. Louis, MO 63110

11th Floor, Mid Campus Center (office)

Admin:
Annalise Seger
segera@wustl.edu

Clinical Interests
  • Breast cancer
Research Interests
  • Breast cancer clinical trials
  • Developmental therapeutics
  • HER2 positive breast cancer
  • Metastatic breast cancer
Research
  • Study Chair for National Cancer Institute Cancer Therapy Evaluation Program Experimental Therapeutics Clinical Trials Network Trial 10382: A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer (NCT04345913).
  • Site Principal Investigator for Phase II ELAINE study: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation. Siteman Cancer Center, Washington University School of Medicine.
  • Site Principal Investigator for ECOG-ACRIN EA1181 CompassHER2-pCR Trial: Comprehensive use of Pathologic response assessment to optimize therapy in HER-2-positive breast cancer. Siteman Cancer Center, Washington University School of Medicine.
  • Site Principal Investigator for Alliance CompassHER2 Residual Disease (RD) Trial, a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and TucatinibT-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer. Siteman Cancer Center, Washington University School of Medicine.
  • Site Principal Investigator for Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06). Siteman Cancer Center, Washington University School of Medicine.
  • Site Principal Investigator for Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer. Siteman Cancer Center, Washington University School of Medicine.
  • Site Principal Investigator for Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM-1 or T-DXd, and/or Tucatinib-containing Regimens (ACE-Breast-03). Siteman Cancer Center, Washington University School of Medicine.
  • Site Principal Investigator for Phase III ELAINE study: An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation. Siteman Cancer Center, Washington University School of Medicine.
Profiles (publications)
WU Physician Bio

Biosketch

Education

  • 2010-2006: MD, University of Iowa Carver College of Medicine, Iowa City, IA
  • 2005-2001: BS in Nutritional Sciences, University of Missouri, Columbia, MO

Post-Graduate Training

  • 2018-2016: Co-Chief Fellow, Hematology/Oncology Fellowship Program, Washington University School of Medicine, St. Louis, MO
  • 2016-2015: Fellow, Hematology/Oncology Fellowship Program, Washington University School of Medicine, St. Louis, MO
  • 2013-2010: Internal Medicine Residency, Washington University School of Medicine/Barnes-Jewish Hospital, St. Louis, MO

Academic Positions & Employment

  • present-2024: Associate Professor, Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
  • 2023-2018: Assistant Professor, Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
  • 2015-2013: BMT Hospitalist, Instructor in Medicine, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO

University & Hospital Appointments

  • present-2021: Associate Member, Siteman Cancer Center, St. Louis, MO

Board Certification

  • 2018: Hematology
  • 2018: Medical Oncology
  • 2013: Internal Medicine

Honors & Awards

  • 2021: Washington University Hematology/Oncology Fellowship Program Teacher of the Year Award
  • 2018: Hanna Jean Khoury Outstanding Graduate Award, Hematology/Oncology Fellowship
  • 2016: R25 STRENGTH Cancer Genomics & Outcomes Research Scholar
  • 2016: Knowlton Incentive for Excellence Award Recipient
  • 2015: Barnes-Jewish Hospital Friends of Nursing Award
  • 2010: John and Oral Sebelin Award for Excellence in Internal Medicine
  • 2010: Margaret Rouse Akin Award in Obstetrics and Gynecology
  • 2009: Alpha Omega Alpha Honor Medical Society
  • 2009: Gold Humanism Honor Society
  • 2009: UI CCOM Community Leadership Excellence Award
  • 2009: Dr. & Mrs. William Alcorn Scholarship, UI College of Medicine
  • 2008: UI Graduate Student Senate Travel Funds Award
  • 2008: Norma Adams Scholarship for volunteerism, UI CCOM
  • 2008: F.E. Taylor Memorial Scholarship, UI College of Medicine
  • 2007: University of Iowa Hospitals & Clinics Department of Obstetrics & Gynecology Award for Outstanding Oral Presentation

Professional Societies

  • present-2021: American Association for Cancer Research
  • present-2015: American Society of Clinical Oncology